Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Maintenance Study in Bipolar I Disorder (CN138-010)
NCT00036348Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2000
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Aripiprazole with Placebo (2 arms). Primary endpoint: Time to relapse for any mood episode at 26 weeks. Started Mar 2000; status: completed.
02
Drugs
aripiprazole
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00036348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036348.